Journey Medical (DERM) Investor presentation summary

Market position and financial highlights

• Commercial-stage pharmaceutical company focused on proprietary and patented dermatology products, targeting a $5.8 billion prescription market including acne, rosacea, and hyperhidrosis.

• 2025 net product revenues reached $61 million with adjusted EBITDA of $2.9 million.

• Solid balance sheet with $24.1 million in cash as of December 31, 2025.

• Market cap of $195 million and 27.5 million shares outstanding as of June 30, 2026.

• Stock added to the Russell 2000 and 3000 indexes in June 2025.

Leadership and commercial organization

• Senior management team has decades of experience in dermatology and pharmaceutical commercialization.

• Leaders have launched and managed brands generating over $2 billion in sales, with many from Medicis, acquired for $2.5 billion in 2012.

• Sales force averages 9 years of dermatology experience, with 280 years combined, and covers 80% of the top 50 U.S. MSAs.

• Incentive programs and equity rewards drive entrepreneurial performance among sales reps.

Product portfolio and growth drivers

• Five core dermatology brands, with Emrosi® as the key growth driver since its April 2025 U.S. launch.

• Emrosi® is a once-daily, extended-release minocycline capsule for rosacea, showing head-to-head superiority over Oracea® in Phase 3 trials.

• Other brands include Qbrexza (hyperhidrosis), Amzeeq (acne), Accutane (severe acne), and Fzilxi (rosacea).

• Emrosi® has three Orange Book-listed patents, with expected exclusivity to 2039.